AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · New Jersey

A1526

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.

Status

Did not pass; died when the session ended

2026 Session

IntroducedJan 13, 2026 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Clinton Calabrese (Democrat)
Type: Therapeutic Access
Substances: Psilocybin

Official text

Summary (from PoliPsy)

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: njleg.state.nj.us

Legislative history

January 13, 2026
Failed
January 13, 2026
Failed
January 13, 2026
Referred
January 13, 2026
Introduced

Loading bill…